Oxford Immunotec to Present at the Jefferies 2017 London Healthcare Conference
November 10 2017 - 9:00AM
YASTEST
OXFORD, United Kingdom and MARLBOROUGH, Mass.,
Nov. 10, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC
(Nasdaq:OXFD), a global, high-growth diagnostics company focused on
developing and commercializing proprietary tests for the management
of underserved immune-regulated conditions, today announced that
Peter Wrighton-Smith, Chief Executive Officer, will present at the
Jefferies 2017 London Healthcare Conference at 8:00 a.m. GMT on
Wednesday, November 15, 2017.
About Oxford
Immunotec
Oxford Immunotec Global PLC is a global,
high-growth diagnostics company focused on developing and
commercializing proprietary tests for the management of underserved
immune-regulated conditions. The Company's first product is
the T-SPOT®.TB test, which is used to
test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50
countries, including the United States, where it has received
pre-market approval from the Food and Drug Administration, Europe,
where it has obtained a CE mark, as well as Japan and China.
The Company's second product line is a range of assays for
tick-borne diseases, such as Lyme disease, obtained through the
acquisitions of Imugen and Immunetics. Also obtained through
these acquisitions is the Company's third product line focused on
screening for Babesia in donated blood, for which the Company is
currently seeking FDA licensure. The Company's fourth product
line is focused on the transplantation market. The Company is
headquartered near Oxford, U.K. and in Marlborough, Mass.
Additional information can be found
at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are
trademarks of Oxford Immunotec Ltd. Immunetics is a trademark
of Immunetics, Inc.
CONTACT:
For Media and Investor
Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Oxford Immunotec via Globenewswire
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Apr 2023 to Apr 2024